These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 11448926

  • 1. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.
    Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L.
    Clin Cancer Res; 2001 Jul; 7(7):2076-84. PubMed ID: 11448926
    [Abstract] [Full Text] [Related]

  • 2. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L.
    Clin Cancer Res; 2003 Oct 15; 9(13):4961-71. PubMed ID: 14581371
    [Abstract] [Full Text] [Related]

  • 3. Geldanamycin, a heat shock protein 90-binding benzoquinone ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from the cytoplasm to the nucleus.
    Czar MJ, Galigniana MD, Silverstein AM, Pratt WB.
    Biochemistry; 1997 Jun 24; 36(25):7776-85. PubMed ID: 9201920
    [Abstract] [Full Text] [Related]

  • 4. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM.
    Cancer Chemother Pharmacol; 2005 Aug 24; 56(2):126-37. PubMed ID: 15841378
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY, Kamal A, Busch D, Thao L, Zhang L, Timony G, Grecko R, Trent K, Lough R, Salazar T, Khan S, Burrows F, Boehm MF.
    J Med Chem; 2004 Jul 15; 47(15):3865-73. PubMed ID: 15239664
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.
    Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM, Egorin MJ.
    Cancer Chemother Pharmacol; 2005 Jan 15; 55(1):21-32. PubMed ID: 15338192
    [Abstract] [Full Text] [Related]

  • 7. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D.
    Cancer Res; 2003 Dec 15; 63(24):8984-95. PubMed ID: 14695217
    [Abstract] [Full Text] [Related]

  • 8. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model.
    Williams CR, Tabios R, Linehan WM, Neckers L.
    J Urol; 2007 Oct 15; 178(4 Pt 1):1528-32. PubMed ID: 17707057
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr 15; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 10. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.
    Soga S, Neckers LM, Schulte TW, Shiotsu Y, Akasaka K, Narumi H, Agatsuma T, Ikuina Y, Murakata C, Tamaoki T, Akinaga S.
    Cancer Res; 1999 Jun 15; 59(12):2931-8. PubMed ID: 10383157
    [Abstract] [Full Text] [Related]

  • 11. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.
    Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, Benjamin IJ, Whitesell L.
    Clin Cancer Res; 2000 Aug 15; 6(8):3312-8. PubMed ID: 10955818
    [Abstract] [Full Text] [Related]

  • 12. Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARbeta activity.
    Sumanasekera WK, Tien ES, Davis JW, Turpey R, Perdew GH, Vanden Heuvel JP.
    Biochemistry; 2003 Sep 16; 42(36):10726-35. PubMed ID: 12962497
    [Abstract] [Full Text] [Related]

  • 13. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW.
    Cancer Res; 2005 Jun 01; 65(11):4929-38. PubMed ID: 15930315
    [Abstract] [Full Text] [Related]

  • 14. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.
    Gougelet A, Bouclier C, Marsaud V, Maillard S, Mueller SO, Korach KS, Renoir JM.
    J Steroid Biochem Mol Biol; 2005 Feb 01; 94(1-3):71-81. PubMed ID: 15862952
    [Abstract] [Full Text] [Related]

  • 15. The Ah receptor is a sensitive target of geldanamycin-induced protein turnover.
    Chen HS, Singh SS, Perdew GH.
    Arch Biochem Biophys; 1997 Dec 01; 348(1):190-8. PubMed ID: 9390191
    [Abstract] [Full Text] [Related]

  • 16. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
    Schulte TW, Neckers LM.
    Cancer Chemother Pharmacol; 1998 Dec 01; 42(4):273-9. PubMed ID: 9744771
    [Abstract] [Full Text] [Related]

  • 17. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37.
    Nony P, Gaude H, Rossel M, Fournier L, Rouault JP, Billaud M.
    Oncogene; 2003 Dec 11; 22(57):9165-75. PubMed ID: 14668798
    [Abstract] [Full Text] [Related]

  • 18. The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin.
    Segnitz B, Gehring U.
    J Biol Chem; 1997 Jul 25; 272(30):18694-701. PubMed ID: 9228040
    [Abstract] [Full Text] [Related]

  • 19. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.
    Zheng FF, Kuduk SD, Chiosis G, Münster PN, Sepp-Lorenzino L, Danishefsky SJ, Rosen N.
    Cancer Res; 2000 Apr 15; 60(8):2090-4. PubMed ID: 10786665
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.
    Münster PN, Srethapakdi M, Moasser MM, Rosen N.
    Cancer Res; 2001 Apr 01; 61(7):2945-52. PubMed ID: 11306472
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.